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The tat gene product of the human immunodeficiency virus type 1 (HIV-1) strongly induces the transcription directed by
the viral long terminal repeat (LTR). Tat acts by interacting with a target RNA element located immediately downstream of
the initiation site. In addition, the action of Tat appears to be assisted by the upstream DNA enhancer elements, including
the binding sites for the NF-kB/Rel family of host transcription factors. In the present study, we demonstrate that Tat
transactivation of the HIV-1 LTR is markedly inhibited by several cytoplasmic inhibitors of NF-kB/Rel, suggesting the critical
involvement of these host transcription factors in the function of the viral Tat protein. Furthermore, the various NF-kB
inhibitors appear to have differential effects on Tat. While IkBa, IkBb, and p100 potently inhibit Tat-mediated transactivation,
p105 fails to inhibit, but even moderately synergizes, the action of Tat. We further demonstrate that the action of these NF-
kB/Rel inhibitors on Tat correlates with their inhibitory activities on the RelA subunit of NF-kB. Finally, we show that a
degradation-resistant IkBa mutant is able to potently inhibit Tat-mediated activation of the HIV-1 LTR in both untreated and
tumor necrosis factor a-stimulated T cells, thus suggesting that such an IkBa mutant may serve as a constitutive repressor
of HIV-1 LTR. q 1996 Academic Press, Inc.
The tat gene product of human immunodeficiency virus plasmic inhibitors and the concomitant nuclear expres-
type 1 (HIV-1) is a potent transcriptional activator of viral sion of select members of NF-kB/Rel (19). The nuclear
gene expression directed by the long terminal repeat NF-kB/Rel in turn binds to the kB enhancer elements in
(LTR) of HIV-1 (reviewed in Ref. 1). Tat acts by specific HIV-1 LTR and participates in the activation of viral gene
binding to the transactivation response region located expression (8).
immediately downstream of the initiation site (1). Tat ap- It has been proposed that NF-kB/Rel plays a role in
pears to increase both the rate of transcriptional initiation the initial induction of HIV-1 expression, and the viral Tat
and the efficiency of transcriptional elongation ( refs. 2– regulator serves to amplify the viral gene expression. It
4, reviewed in Ref. 5). Tat-mediated stimulation of tran- is not clear, however, whether the action of Tat strictly
scription involves interactions between this viral trans- requires the participation of the NF-kB/Rel transcription
activator and cellular transcription factors such as Sp-1 factors.
and the basal transcription factor TFIID (6, 7). In addition, To better understand the function of NF-kB/Rel in the
the NF-kB/Rel family of inducible transcription factors activation of the HIV-1 LTR, we investigated the effects
has been suggested to contribute to the enhanced ex- of various NF-kB/Rel inhibitors on Tat-mediated activa-
pression of HIV-1 LTR in activated T cells (8). tion of the HIV-1 LTR using transient transfection and
The NF-kB/Rel family contains various dimeric com- reporter gene assays. For these studies, human Jurkat T
plexes composed of a set of structurally related polypep- cells were transfected with a luciferase reporter plasmid
tides, including p50 (NF-kB1), p52 (NF-kB2), RelA (pre- driven by the HIV-1 LTR (HIV-1 LTR-luciferase) together
viously named p65), RelB, and the proto-oncoprotein with the tat cDNA expression vector either in the absence
c-Rel (reviewed in Ref. 9). In resting T cells, these NF- or in the presence of various IkB expression vectors
kB/Rel complexes are sequestered in the cytoplasm as (Figs. 1A and 1B). As expected, Tat potently activated the
latent precursors by a family of ankyrin motif-rich inhibi- LTR, leading to the enhanced expression of the luciferase
tory proteins (10) including IkBa (11, 12), IkBb (13), p105 reporter gene (Fig. 1A, column 2). However, Tat only mod-
(14–16), and p100 (16 – 18). Various immunological stim- erately activated the HIV-1 LTR that lacks the kB en-
uli, such as the cytokine tumor necrosis factor a (TNF- hancer elements (HIV-1 LTRDkB, column 3). To examine
a), induce the degradation of one or more of these cyto- whether Tat-mediated activation of the wild-type HIV-1
LTR requires NF-kB/Rel factors present in these cells,
the effect of various NF-kB/Rel inhibitory proteins on the1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (717) 531-6522. transactivation activity of Tat was investigated by cotran-
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sfection studies. As shown in Fig. 1B, the transactivation
activity of Tat was significantly and dose-dependently
inhibited by several NF-kB/Rel inhibitors, including IkBa
(columns 1–4), IkBb (columns 5–8), and p100 (columns
9–12). This inhibitory action was not due to the inhibition
of Tat expression since Tat-mediated activation of the
HIV-1 LTR DkB was not significantly influenced by IkBa
(Fig. 1C) as well as the other inhibitors (data not shown).
These results indicated that the transactivation function
of Tat required the basal activity of NF-kB/Rel that could
be detected in these cells (data not shown). Of note,
although p105 had been demonstrated to be one of the
cytoplasmic inhibitors of NF-kB/Rel (14–16), it failed to
inhibit Tat-mediated activation of the LTR (Fig. 1B, col-
umns 13–16). In fact, at low concentration, p105 exhib-
ited a moderate, but significant, synergistic effect on Tat
(column 14).
We next explored the possible mechanism underlying
the differential effects of the various IkBs on the action
of Tat. Since RelA has been shown to be a potent tran-
scriptional activator of HIV-1 kB enhancer (20), the inhibi-
tory function of the different IkB molecules on the kB
binding activity of the RelA subunit of NF-kB was ana-
lyzed. For these studies, we used COS7 cells which had
high efficiency of transfection that allowed us to detect
the DNA binding activity of transfected RelA using elec-
trophoresis mobility shift assays (EMSA). As shown in
Fig. 2, the cells were transfected with either a parental
vector (pCMV4) lacking a cDNA insert (lane 1) or the
RelA cDNA expression vector in the absence (lane 2) or
presence of varied amounts of different IkB expression
vectors (lanes 3–14). EMSA analyses of the nuclear ex-
tracts revealed specific binding of the transfected RelA
to the kB probe, which formed a DNA/protein complex
(lane 2). As expected, the RelA DNA binding activity was
potently inhibited by IkBa (lanes 3–5), as well as IkBb
(lanes 6–8) and p100 (lanes 9–11). In sharp contrast,
expression of p105 in the cells did not inhibit but even
enhanced the DNA binding activity of RelA (lanes 12–
14). Parallel reporter gene assays revealed that unlike
other IkB molecules, pl05 failed to inhibit RelA-mediated
transactivation of the HIV-1 kB enhancer (data not
shown). While the underlying mechanism remains to be
further investigated, these results demonstrate that the
effects of the various IkB molecules on Tat correlated
with their functional specificity on the RelA transcriptional
activator.
FIG. 1. Inhibition of Tat-mediated activation of HIV-1 LTR by different
NF-kB/Rel inhibitors. (A) Human Jurkat T cells (5 1 106) were the basal level measured in cells transfected with the parental vectorp
transfected using DEAE-Dextran (24) with 0.4 mg of the HIV-1 LTR- CMV4. The values shown in this and all the following luciferase assays
luciferase reporter plasmid [HIV-1 LTR was transferred from the HIV- are representative of three independent experiments. The absolute
1 LTR CAT (31) into the pGL2 basic vector (Promega) in front of the values for the wild-type HIV-1 LTR luciferase activity in the mock-and
luciferase gene] in the absence (column 1) or presence (column 2) of Tat-transfected cells are about 1.5 1 104 and 4.5 1 105 cpm, respec-
0.2 mg tat cDNA expression vector, pSV2Tat72 (32). In column 3, a tively. (B) Luciferase assays of cells transfected with 0.4 mg HIV-1 LTR-
luciferase reporter driven by the HIV-1 LTR lacking the kB elements luciferase reporter and 0.2 mg pSV2Tat72, along with the indicated
(HIV-1 LTR DkB-luciferase) was cotransfected with pSV2Tat72. At 40 amounts of the various IkB molecules. (C) Luciferase assays of cells
hr posttransfection, the cells were collected for luciferase assay (Pro- transfected with 0.4 mg HIV-1 LTRDkB-luciferase reporter and 0.2 mg
mega). Luciferase activity is presented as fold induction relative to pSV2Tat72, along with the indicated amounts of IkBa.
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While it remains to be further investigated how Tat
overrides the action of IkBa, our studies strongly sug-
gest that Tat-mediated transactivation of the HIV-1 LTR
critically requires the action of NF-kB/Rel, especially
the transactivator RelA. Our results are in support of
the previous studies showing the involvement of RelA
in the activation of HIV-1 LTR (28, 29). Our studies
also have confirmed and extended a recent report (30)
demonstrating that the function of Tat is tightly depen-
dent on the kB enhancers present in the HIV-1 LTR.
FIG. 2. Inhibition of RelA DNA binding activity by IkBa, IkBb, and Together, these studies strongly suggest that the host
p100, but not by p105. Monkey kidney COS7 cells were transfected by transcription factor NF-kB is critically required for HIV-
DEAE-Dextran (25) with either the parental vector pCMV4 (33) (lane 1)
1 gene expression.or 0.4 mg pCMV4-RelA cDNA expression vector (25) either alone (lane
2) or together with the indicated amounts of various pCMV4-based
IkB expression constructs subcloned from the corresponding cDNAs,
including IkBa (lanes 1–4, Ref. 12), IkBb (lanes 5–8, Ref. 13), p100
(lanes 9–12, Ref. 34), and p105 (lanes 13–16, Ref. 35) (lanes 3–14). At
40 hr posttransfection, nuclear extracts were isolated (26) and sub-
jected to electrophoresis mobility shift assays (EMSA) using a 32P-
radiolabeled palindromic kB probe, kB-pd (27).
Recent studies have suggested that IkBa is the major
inhibitor regulating the immediate early nuclear expres-
sion of the RelA-containing NF-kB complex, which occurs
in response to various cytokines and mitogens (21).
These immunological inducers stimulate the phosphory-
lation of IkBa at its N-terminal region, which leads to
rapid degradation of IkBa (22, 23). Interestingly, an IkBa
mutant lacking the N-terminal 71 amino acids (IkBaDN)
becomes resistant to cellular stimulation and serves as
a constitutive inhibitor of NF-kB (22). To further correlate
the action of IkBa on Tat and RelA, we next compared
the Tat-inhibitory activities of IkBaDN and its wild type.
For these studies, human Jurkat T cells were cotrans-
fected with the HIV-1 LTR-luciferase reporter, Tat, and
either the wild-type IkBa (Fig. 3A, columns 2 and 3) or
IkBaDN (columns 4 and 5). Remarkably, these studies
revealed that the degradation-resistant IkBa mutant
(lanes 4 and 5) exhibited a markedly more potent inhibi-
tory effect on Tat compared to that of the wild-type IkBa
(lanes 2 and 3). Of note, the two forms of IkBa had similar
inhibitory activities on RelA-mediated activation of the kB
enhancer (Fig. 3B). These findings raised the possibility
that the HIV-1 Tat protein might override the inhibitory
action of IkBa. To test this possibility, luciferase reporter
gene assays were performed using increasing amounts
of Tat expression vector (Fig. 4A). These luciferase FIG. 3. Inhibition of Tat-mediated activation of the HIV-1 LTR (A)
assays revealed that expression of increasing amounts and RelA-mediated activation of the HIV-1 kB enhancer (B) by the
wild-type IkBa (IkBaWT) and its degradation-resistant mutant,of Tat protein in the cells significantly overrode the inhibi-
IkBaDN. Jurkat cells were transfected with pSV2Tat72 (A) or RelAtory effect of the wild-type IkBa (columns 1–5). In sharp
(B), either alone or together with the indicated amounts of IkBa orcontrast, Tat induced only a slight increase of the lucifer-
its mutant IkBaDN (the N-terminal 36 amino acids were removed
ase activity in cells expressing the degradation-resistant from the wild-type IkBa by polymerase chain reaction), along with
IkBa mutant (IkBaDN, lanes 6–10). Similar reporter the HIV-1 LTR-luciferase (A) or the kB-TATA-luciferase reporter [the
insert of kB-TATA-CAT (36), containing the HIV-1 kB enhancer andgene studies revealed that IkBaDN potently inhibited
TATA box, was transferred into the pGL2 basic plasmid 5* of theTat-mediated activation of HIV-1 LTR in both untreated
luciferase gene (Promega)]. (B). Luciferase was assayed as de-(Fig. 4B, columns 1 and 2) and TNF-a-stimulated (col-
scribed in the legend for Fig. 1.
umns 3 and 4) cells.
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